Literature DB >> 21418670

Hyperthyroidism (primary).

Birte Nygaard1.   

Abstract

INTRODUCTION: Hyperthyroidism is characterised by high levels of serum thyroxine and triiodothyronine, and low levels of thyroid-stimulating hormone. The main causes of hyperthyroidism are Graves' disease, toxic multinodular goitre, and toxic adenoma. About 20 times more women than men have hyperthyroidism. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for primary hyperthyroidism? What are the effects of surgical treatments for primary hyperthyroidism? What are the effects of treatments for subclinical hyperthyroidism? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 15 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding thyroxine to antithyroid drugs (carbimazole, propylthiouracil, and thiamazole), antithyroid drugs (carbimazole, propylthiouracil, and thiamazole), radioactive iodine, and thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21418670      PMCID: PMC3275323     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  28 in total

1.  Cancer mortality after iodine-131 therapy for hyperthyroidism.

Authors:  P Hall; G Berg; G Bjelkengren; J D Boice; U B Ericsson; A Hallquist; M Lidberg; G Lundell; J Tennvall; K Wiklund
Journal:  Int J Cancer       Date:  1992-04-01       Impact factor: 7.396

2.  High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland.

Authors:  P Laurberg; K M Pedersen; H Vestergaard; G Sigurdsson
Journal:  J Intern Med       Date:  1991-05       Impact factor: 8.989

3.  The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.

Authors:  M P Vanderpump; W M Tunbridge; J M French; D Appleton; D Bates; F Clark; J Grimley Evans; D M Hasan; H Rodgers; F Tunbridge
Journal:  Clin Endocrinol (Oxf)       Date:  1995-07       Impact factor: 3.478

4.  Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis.

Authors:  Junichi Tajiri; Shiro Noguchi
Journal:  Thyroid       Date:  2004-06       Impact factor: 6.568

5.  Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.

Authors:  C T Sawin; A Geller; P A Wolf; A J Belanger; E Baker; P Bacharach; P W Wilson; E J Benjamin; R B D'Agostino
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

6.  Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.

Authors:  L Tallstedt; G Lundell; O Tørring; G Wallin; J G Ljunggren; H Blomgren; A Taube
Journal:  N Engl J Med       Date:  1992-06-25       Impact factor: 91.245

7.  Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study.

Authors:  Lars Frost; Peter Vestergaard; Leif Mosekilde
Journal:  Arch Intern Med       Date:  2004 Aug 9-23

8.  Goitre size and outcome of medical treatment of Graves' disease.

Authors:  P Laurberg; P E Buchholtz Hansen; E Iversen; S Eskjaer Jensen; J Weeke
Journal:  Acta Endocrinol (Copenh)       Date:  1986-01

9.  Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.

Authors:  Frank Träisk; Leif Tallstedt; Mirna Abraham-Nordling; Tommy Andersson; Gertrud Berg; Jan Calissendorff; Bengt Hallengren; Pavo Hedner; Mikael Lantz; Ernst Nyström; Vesna Ponjavic; Adam Taube; Ove Törring; Göran Wallin; Peter Asman; Göran Lundell
Journal:  J Clin Endocrinol Metab       Date:  2009-09-01       Impact factor: 5.958

10.  A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.

Authors:  D Reinwein; G Benker; J H Lazarus; W D Alexander
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

View more
  1 in total

1.  Relationship between body mass index and external exposure in hyperthyroid patients treated with iodine-131.

Authors:  Ghazal Yazdanpanah; Mohammad Nematdar; Hoda Talebian; Ali Shabestani Monfared
Journal:  Am J Nucl Med Mol Imaging       Date:  2022-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.